Ankit Mahadevia, See Remarks at Spero Therapeutics, Inc. (SPRO), sold 7,952 shares at $17.62 ($140K) on 2018-07-05, disclosed to the SEC on 2018-07-06.
Open-market sale of $140k SPRO by See Remarks. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $17.62 | 3,076 | $54K | 38.7% |
| 2 | $17.62 | 3,076 | $54K | 38.7% |
| 3 | $17.50 | 500 | $9K | 6.2% |
| 4 | $17.55 | 100 | $2K | 1.3% |
| 5 | $17.55 | 100 | $2K | 1.3% |
| 6 | $17.58 | 400 |
| $7K |
| 5.0% |
| 7 | $17.62 | 100 | $2K | 1.3% |
| 8 | $17.70 | 100 | $2K | 1.3% |
| 9 | $17.71 | 100 | $2K | 1.3% |
| 10 | $17.90 | 200 | $4K | 2.6% |
| 11 | $17.92 | 200 | $4K | 2.6% |
| Total | $17.63 avg | 7,952 | $140K | 100% |
| Filing → |
| SPRO | SELL | 2024-08-29 | $8K | — | Filing → |
| SPRO | SELL | 2024-02-05 | $175K | — | Filing → |
| SPRO | SELL | 2023-08-30 | $11K | — | Filing → |